Trial ID or NCT#

NCT02762266

Status

RECRUITING

Purpose

This randomized phase III trial studies how well transarterial chemoembolization (TACE) works compared to stereotactic body radiation therapy (SBRT) or stereotactic ablative radiation therapy (SABR) in patients with liver cancer that remain after attempts to remove the cancer have been made (residual) or has come back (recurrent). TACE is a minimally invasive, image-guided treatment procedure that uses a catheter to deliver both chemotherapy medication and embolization materials into the blood vessels that lead to the tumors. SBRT or SABR may be able to send radiation directly to the tumor and cause less damage to normal liver tissue. It is not yet known whether TACE is more effective than SBRT or SABR in treating patients with persistent or recurrent liver cancer who have undergone initial TACE.

Official Title

International Randomized Study of Transarterial Chemoembolization (TACE) Versus Stereotactic Body Radiotherapy (SBRT) / Stereotactic Ablative Radiotherapy (SABR) for Residual or Recurrent Hepatocellular Carcinoma After Initial TACE

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Daniel Chang
Radiation oncologist
Sue and Bob McCollum Professor
Albert Koong, MD, PhD
Daniel Sze, MD, PhD
Interventional radiologist
Professor of Radiology (General Radiology) at the Stanford University Medical Center
Nishita Kothary, MD
Interventional radiologist
Professor of Radiology (General Radiology) at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

Rachel Freiberg
(650) 725-0438